Rocket Pharmaceuticals, Inc. (RCKT)
Automate Your Wheel Strategy on RCKT
With Tiblio's Option Bot, you can configure your own wheel strategy including RCKT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RCKT
- Rev/Share 0.0
- Book/Share 3.7435
- PB 0.756
- Debt/Equity 0.0615
- CurrentRatio 9.1896
- ROIC -0.616
- MktCap 304898540.0
- FreeCF/Share -1.9336
- PFCF -1.4323
- PE -1.2075
- Debt/Assets 0.0538
- DivYield 0
- ROE -0.6492
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RCKT | Evercore ISI | Outperform | In-line | -- | $5 | May 30, 2025 |
| Downgrade | RCKT | Leerink Partners | Outperform | Market Perform | -- | $8 | May 28, 2025 |
| Downgrade | RCKT | Jefferies | Buy | Hold | -- | $2.5 | May 28, 2025 |
| Downgrade | RCKT | Morgan Stanley | Overweight | Equal Weight | -- | $7 | May 28, 2025 |
| Downgrade | RCKT | Goldman | Neutral | Sell | -- | $2 | May 28, 2025 |
| Downgrade | RCKT | JP Morgan | Overweight | Neutral | -- | -- | May 28, 2025 |
| Downgrade | RCKT | Needham | Buy | Hold | -- | -- | May 27, 2025 |
| Downgrade | RCKT | TD Cowen | Buy | Hold | -- | -- | May 27, 2025 |
| Initiation | RCKT | BMO Capital Markets | -- | Outperform | -- | $50 | March 12, 2025 |
| Initiation | RCKT | Wedbush | -- | Outperform | -- | $32 | Dec. 30, 2024 |
News
Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Published: June 20, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ROCKET PHARMACEUTICALS, INC. (RCKT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What.
Read More
INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Robbins Geller
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934.
Read More
Faruqi & Faruqi Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT
Published: June 20, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , June 20, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. ("Rocket" …
Read More
Rocket Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against RCKT
Published: June 20, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.
Read More
Shareholders that lost money on Rocket Pharmaceuticals, Inc.(RCKT) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
Published: June 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).
Read More
Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025
Published: June 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 17, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153464&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
Published: June 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
Published: June 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
RCKT Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Rocket Pharmaceuticals, Inc. Class Action Lawsuit
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) securities between February 7, 2025 and May 26, 2025.Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
Read More
Securities Lawsuit Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors - Contact Levi & Korsinsky Before August 11, 2025
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153354&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq.
Read More
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Over Securities Violations - Contact Levi & Korsinsky Today
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153345&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.
Read More
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights – RCKT
Published: June 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit And Upcoming Deadlines - RCKT
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Securities Lawsuit Alert: Rocket Pharmaceuticals, Inc. (RCKT) - Contact Levi & Korsinsky Before August 11, 2025
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153319&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.
Read More
Securities Class Action Lawsuit Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - Levi & Korsinsky Represents Shareholders
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153290&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Urges Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153250&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq.
Read More
Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT)
Published: June 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
Read More
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=152995&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
Published: June 13, 2025 by: PRNewsWire
Sentiment: Neutral
RCKT Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , June 13, 2025 /PRNewswire/ -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al.
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.
Read More
Levi & Korsinsky Urges Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=152840&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Rocket Pharmaceuticals, Inc. (RCKT)
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”).
Read More
Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Published: June 12, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 11, 2025
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=152818&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT.
Read More
About Rocket Pharmaceuticals, Inc. (RCKT)
- IPO Date 2015-02-18
- Website https://rocketpharma.com
- Industry Biotechnology
- CEO Dr. Gaurav D. Shah M.D.
- Employees 299